Canaccord lowered the firm’s price target on Enovix (ENVX) to $21 from $22 and keeps a Buy rating on the shares. The firm says the company’s statement that it sees “additional lifecycle testing following…design revision” has added about 3 to 6 months to the ramp schedule, but while it admits to being “a little frustrated with another ramp delay,” it is comforted by what it views as Enovix’s strong management team, great technology, and healthy balance sheet.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENVX:
- Enovix’s Strategic Partnership with Honor: A Buy Rating Amidst Challenges and Opportunities
- Enovix Corporation Reports Strong Q3 2025 Results
- Enovix sees Q4 non-GAAP EPS (16c)-(20c), consensus (14c)
- Enovix reports Q3 EPS (14c), consensus (16c)
- Enovix options imply 16.9% move in share price post-earnings